Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Equity

Summit Therapeutics (SMMT) EBITDA Margin (2022 - 2024)

Summit Therapeutics' EBITDA Margin history spans 2 years, with the latest figure at 1945.04% for Q2 2024.

  • For Q2 2024, EBITDA Margin changed N/A year-over-year to 1945.04%; the TTM value through Mar 2025 reached 7761.73%, up 401044.0%, while the annual FY2022 figure was 11131.63%, 632207.0% down from the prior year.
  • EBITDA Margin reached 1945.04% in Q2 2024 per SMMT's latest filing, up from 1392.95% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 1945.04% in Q2 2024 to a low of 9742.73% in Q3 2022.